The ulinastatin group had lower incidence of new-onset organ failure ( 10 vs. 26 patients , p = 0.003 ) , more ventilator-free days ( mean SD 19.4 10.6 days vs. 10.2 12.5 days , p = 0.019 ) , and shorter hospital stay ( 11.8 7.1 days vs. 24.2 7.2 days , p < 0.001 ) .